BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25354813)

  • 1. Oesophageal cancer: assessment of tumour response to chemoradiotherapy with tridimensional CT.
    Alfieri R; Pintacuda G; Cagol M; Occhipinti T; Capraro I; Scarpa M; Zanchettin G; Cavallin F; Michelotto M; Giacomelli L; Ancona E; Castoro C
    Radiol Med; 2015 May; 120(5):430-9. PubMed ID: 25354813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer.
    van Heijl M; Phoa SS; van Berge Henegouwen MI; Omloo JM; Mearadji BM; Sloof GW; Bossuyt PM; Hulshof MC; Richel DJ; Bergman JJ; Ten Kate FJ; Stoker J; van Lanschot JJ
    Eur J Surg Oncol; 2011 Dec; 37(12):1064-71. PubMed ID: 21944048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer.
    Konieczny A; Meyer P; Schnider A; Komminoth P; Schmid M; Lombriser N; Weishaupt D
    Eur Radiol; 2013 Sep; 23(9):2492-502. PubMed ID: 23645329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma.
    Blom RL; Steenbakkers IR; Lammering G; Vliegen RF; Belgers EJ; de Jonge C; Schreurs WM; Nap M; Sosef MN
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1500-6. PubMed ID: 23764889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
    Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
    Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy.
    Heethuis SE; van Rossum PS; Lips IM; Goense L; Voncken FE; Reerink O; van Hillegersberg R; Ruurda JP; Philippens ME; van Vulpen M; Meijer GJ; Lagendijk JJ; van Lier AL
    Radiother Oncol; 2016 Jul; 120(1):128-35. PubMed ID: 27296409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the computed tomography perfusion imaging improve the diagnostic accuracy in the response evaluation of esophageal carcinoma to the neoadjuvant chemoradiotherapy? Preliminary study.
    Djuric-Stefanovic A; Saranovic D; Micev M; Stankovic V; Plesinac-Karapandzic V; Pesko P; Stojakov D; Sabljak P; Bjelovic M
    J BUON; 2014; 19(1):237-44. PubMed ID: 24659670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer.
    Lee SM; Kim SH; Lee JM; Im SA; Bang YJ; Kim WH; Kim MA; Yang HK; Lee HJ; Kang WJ; Han JK; Choi BI
    Abdom Imaging; 2009 Jul; 34(4):430-40. PubMed ID: 18546037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of the metabolically active tumour volume].
    Paumier A; Marquis A; Trémolières P; Lacombe M; Capitain O; Septans AL; Peyraga G; Gustin P; Vénara A; Ménager É; Visvikis D; Couturier O; Rio E; Hatt M
    Cancer Radiother; 2016 Feb; 20(1):24-9. PubMed ID: 26762703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.
    Calais J; Dubray B; Nkhali L; Thureau S; Lemarignier C; Modzelewski R; Gardin I; Di Fiore F; Michel P; Vera P
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):858-67. PubMed ID: 25680400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between CT volume measurement and histopathological assessment of response to neoadjuvant therapy in rectal cancer.
    Pomerri F; Pucciarelli S; Gennaro G; Maretto I; Nitti D; Muzzio PC
    Eur J Radiol; 2012 Dec; 81(12):3918-24. PubMed ID: 22902408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New application of dual point 18F-FDG PET/CT in the evaluation of neoadjuvant chemoradiation response of locally advanced rectal cancer.
    Yoon HJ; Kim SK; Kim TS; Im HJ; Lee ES; Kim HC; Park JW; Chang HJ; Choi HS; Kim DY; Oh JH
    Clin Nucl Med; 2013 Jan; 38(1):7-12. PubMed ID: 23242038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer.
    Metser U; Rashidi F; Moshonov H; Wong R; Knox J; Guindi M; Darling G
    Ann Nucl Med; 2014 May; 28(4):295-303. PubMed ID: 24474598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degree of tumor shrinkage following neoadjuvant chemoradiotherapy: a potential predictor for complete pathological response in esophageal cancer?
    Voncken FE; Jiang H; Kim J; Guindi M; Brierley J; Knox J; Liu G; Horgan AM; Lister J; Darling G; Metser U; Wong RK
    Dis Esophagus; 2014 Aug; 27(6):552-9. PubMed ID: 23121504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
    Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
    Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of 2-Deoxy-2-[18F]-Fluoro-D-Glucose PET/CT in Patients With Locally Advanced Esophageal Cancer Undergoing Neoadjuvant Chemoradiotherapy Before Surgery: A Nonparametric Approach.
    Giorgetti A; Pallabazzer G; Ripoli A; Solito B; Genovesi D; Lencioni M; Fabrini MG; D'Imporzano S; Pieraccini L; Marzullo P; Santi S
    Medicine (Baltimore); 2016 Mar; 95(13):e3151. PubMed ID: 27043676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma.
    Elliott JA; O'Farrell NJ; King S; Halpenny D; Malik V; Muldoon C; Johnston C; Reynolds JV
    Br J Surg; 2014 Dec; 101(13):1702-11. PubMed ID: 25351460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
    Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
    Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.